Rockefeller Capital Management
KYMR icon

Rockefeller Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Rockefeller Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.7M Buy
32,367
+6,834
+27% +$541K ﹤0.01% 1167
2025
Q4 		$1.99M Buy
25,533
+25,415
+21,538% +$1.72M ﹤0.01% 1251
2025
Q3 		$6.68K Buy
+118
New +$5.32K ﹤0.01% 3790
2023
Q1 		– Sell
-10,423
Closed -$260K – 3030
2022
Q4 		$260K Buy
10,423
+223
+2% +$5.95K ﹤0.01% 1543
2022
Q3 		$222K Buy
+10,200
New +$269K ﹤0.01% 1610

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Rockefeller Capital Management's KYMR Position: Q1 2026 in Review

Rockefeller Capital Management increased its Kymera Therapeutics (KYMR) stake by 27% in Q1 2026, buying an estimated $541K and bringing the position to 32,367 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Rockefeller Capital Management first reported a position in KYMR in Q3 2022 and has held it in 5 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Rockefeller Capital Management held 32,367 shares of Kymera Therapeutics worth $2.7M as of Q1 2026.
  • Rockefeller Capital Management bought 6,834 Kymera Therapeutics shares in Q1 2026, an estimated $541K.
  • Kymera Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1167 holding.
  • Rockefeller Capital Management first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.